Are safety lead-in phase II clinical trials really safe?
Background/AimsPhase II trials with a safety lead-in (SLI), allowing one or two dose de-escalations based on toxicities from the first several patients at a dose, are increasingly common in oncology. Despite increased demand, formal evaluation of SLI designs remains limited to dose selection without evaluating the perf...